0
Biohaven Pharmaceutical Holding Company Ltd. Banner Image

Biohaven Pharmaceutical Holding Company Ltd. has reached its limit for free report views

Work for Biohaven Pharmaceutical Holding Company Ltd.? Upgrade Your Profile and unlock all your annual reports.

Biohaven Pharmaceutical Holding Company Ltd.

  • Ticker BHVN
    Exchange NYSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Biohaven Pharmaceutical Holding Company Ltd. Logo Image
  • 501-1000 Employees
  • Based in New Haven, Connecticut
Biohaven is a biopharmaceutical company focused on the development and commercialization of innovative best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases. Biohaven's neuroinnovation portfolio includes FDA-approved NURTECâ„¢ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidatesMore across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and myeloperoxidase (MPO) inhibition for multiple system atrophy and amyotrophic lateral sclerosis.
Biohaven Pharmaceutical Holding Company Ltd.

Most Recent Annual Report

Biohaven Pharmaceutical Holding Company Ltd. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Biohaven Pharmaceutical Holding Company Ltd. has reached its limit for free report views.

Older/Archived Annual Reports